Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionCalamos Advisors LLC
Latest Disclosed Ownership77,886 shares
Latest Disclosed Value $ 34,779,214
Calamos Advisors LLC ownership in VRTX / Vertex Pharmaceuticals Incorporated

On May 4, 2026 - Calamos Advisors LLC filed a 13F-HR form disclosing ownership of 77,886 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $34,779,214 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 43,969 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 77.14% during the quarter. The current value of the position is $34,801,801 USD.

Calamos Advisors LLC has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-04 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 77,886 33,917 77.14 34,779 74.48 0.1227
2026-01-29 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 43,969 -1,784 -3.90 19,934 11.25 0.0749
2025-10-20 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 45,753 0 0.00 17,919 -12.03 0.0662
2025-08-08 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 45,753 0 0.00 20,369 -8.17 0.0802
2025-04-29 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 45,753 509 1.13 22,182 21.75 0.0966
2025-01-24 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 45,244 0 0.00 18,220 -13.42 0.0762
2024-11-07 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 45,244 -1,189 -2.56 21,042 -3.32 0.0910
2024-07-25 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 46,433 -1,691 -3.51 21,764 8.19 0.0967
2024-05-08 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 48,124 -21,048 -30.43 20,116 -28.53 0.0953
2024-01-31 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 69,172 -923 -1.32 28,145 15.47 0.1365
2023-10-26 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 70,095 0 0.00 24,375 -1.19 0.1266
2023-07-28 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 70,095 -11,477 -14.07 24,667 -4.02 0.1220
2023-05-04 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 81,572 -10,185 -11.10 25,701 -3.01 0.1255
2023-01-26 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 91,757 -16,171 -14.98 26,498 -15.21 0.1243
2022-10-24 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 107,928 37 0.03 31,249 2.78 0.1429
2022-08-01 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 107,891 2,904 2.77 30,403 10.97 0.1311
2022-05-03 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 104,987 13,837 15.18 27,398 36.87 0.1029
2022-02-01 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 91,150 -19,807 -17.85 20,017 -0.54 0.0748
2021-10-26 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 110,957 -17,046 -13.32 20,126 -22.02 0.0879
2021-07-22 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 128,003 -71,266 -35.76 25,809 -39.73 0.1179
2021-04-12 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 199,269 57,190 40.25 42,821 27.52 0.2336
2021-01-27 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 142,079 -4,076 -2.79 33,579 -15.57 0.1949
2020-10-26 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 146,155 -25,789 -15.00 39,772 -20.32 0.2560
2020-07-27 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 171,944 57,288 49.97 49,917 82.97 0.3528
2020-04-28 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 114,656 72,931 174.79 27,282 198.62 0.2141
2020-01-15 2019-12-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 41,725 -727 -1.71 9,136 27.03 0.0452
2019-10-21 2019-09-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 42,452 3,681 9.49 7,192 1.15 0.0392
2019-08-07 2019-06-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 38,771 1,928 5.23 7,110 4.91 0.0395
2019-04-12 2019-03-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 36,843 408 1.12 6,777 12.24 0.0423
2019-01-24 2018-12-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 36,435 5,455 17.61 6,038 1.12 0.0399
2018-10-22 2018-09-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 30,980 -3,148 -9.22 5,971 2.95 0.0328
2018-07-17 2018-06-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 34,128 4,028 13.38 5,800 18.22 0.0354
2018-04-13 2018-03-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 30,100 1,418 4.94 4,906 14.15 0.0319
2018-02-13 2017-12-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 28,682 -547 -1.87 4,298 -3.29 0.0219
2017-10-25 2017-09-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 29,229 1,022 3.62 4,444 22.26 0.0344
2017-08-09 2017-06-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 28,207 -14,931 -34.61 3,635 13.42 0.0269
2014-02-14 2013-12-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 43,138 43,138 3,205 0.0204
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2019-04-12 2019-03-31 13F VERTEX PHARMACEUTICALS COMMON STOCK Put 0 -100.00 0 -100.00 n/a n/a n/a
2019-01-24 2018-12-31 13F VERTEX PHARMACEUTICALS COMMON STOCK Put 31,000 5,137 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.